

Status: Currently Official on 16-Feb-2025
 Official Date: Official as of 01-Aug-2017
 Document Type: USP Monographs
 DocId: GUID-569291B4-AE82-42AD-8933-F963EB6002BB_1_en-US
 DOI: https://doi.org/10.31003/USPNF_M78765_01_01
 DOI Ref: slg98

© 2025 USPC
 Do not distribute

Sulfacetamide Sodium and Prednisolone Acetate Ophthalmic Ointment

DEFINITION

Sulfacetamide Sodium and Prednisolone Acetate Ophthalmic Ointment is a sterile ointment containing NLT 90.0% and NMT 110.0% of the labeled amounts of sulfacetamide sodium ($C_8H_9N_2NaO_3S \cdot H_2O$) and prednisolone acetate ($C_{23}H_{30}O_6$).

IDENTIFICATION

- **A.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the tests for *Sulfacetamide Sodium* and *Prednisolone Acetate* in the Assay.
- **B.** The UV absorption spectra of the major peak of the *Sample solution* and that of the *Standard solution* exhibit maxima and minima at the same wavelengths, as obtained in the tests for *Sulfacetamide Sodium* and *Prednisolone Acetate* in the Assay.

ASSAY

• SULFACETAMIDE SODIUM

Diluent: Dilute [methanol](#) (1 in 5)

Mobile phase: [Methanol](#), [glacial acetic acid](#), and [water](#) (100:10:890), filtered and degassed

Standard solution: Transfer about 50 mg of [USP Sulfacetamide Sodium RS](#) to a 40-mL centrifuge tube. Add 10.0 mL of *Diluent*, insert the stopper in the tube, and mix using a vortex mixer for about 3 min to dissolve. Add 7.5 mL of [heptane](#), insert the stopper in the tube, and mix using a vortex mixer for another 3 min. Centrifuge to effect separation of the phases. Withdraw and discard the upper heptane layer. Transfer 3.0 mL of the bottom layer to a 500-mL volumetric flask, add *Diluent* to volume, and mix.

System suitability solution: Dissolve 3 mg of [sulfanilamide](#) in 100 mL of the *Standard solution*, and mix.

Sample solution: Transfer a quantity of Ophthalmic Ointment nominally equivalent to about 100 mg of sulfacetamide sodium to a 40-mL centrifuge tube. Add 15.0 mL of [heptane](#), insert the stopper in the tube, and mix using a vortex mixer for about 3 min to dissolve the Ophthalmic Ointment. Add 20.0 mL of *Diluent*, insert the stopper in the tube, and mix using a vortex mixer for 3 min. Centrifuge to effect separation of the phases. Withdraw and discard the upper heptane layer. Transfer 3.0 mL of the bottom layer to a 500-mL volumetric flask, dilute with *Diluent* to volume, and mix.

Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

Mode: LC

Detector: 254-nm diode array

Column: 4.6-mm × 25-cm; packing [L1](#)

Flow rate: 1.5 mL/min

Injection volume: 90 µL

System suitability

Samples: *Standard solution* and *System suitability solution*

Suitability requirements

Resolution: NLT 3 between the sulfacetamide and sulfanilamide peaks, *System suitability solution*

Column efficiency: NLT 1500 theoretical plates, *Standard solution*

Relative standard deviation: NMT 2.0%, *Standard solution*

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of sulfacetamide sodium ($C_8H_9N_2NaO_3S \cdot H_2O$) in the portion of Ophthalmic Ointment taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$$

r_U = peak response of sulfacetamide sodium from the *Sample solution*

r_S = peak response of sulfacetamide sodium from the *Standard solution*

C_S = concentration of [USP Sulfacetamide Sodium RS](#), calculated on the anhydrous basis, in the *Standard solution* (mg/mL)

C_U = nominal concentration of sulfacetamide sodium in the *Sample solution* (mg/mL)

M_{r1} = molecular weight of sulfacetamide sodium monohydrate, 254.24

M_{r2} = molecular weight of anhydrous sulfacetamide sodium, 236.23

Acceptance criteria: 90.0%–110.0%

• **PREDNISOLONE ACETATE**

Diluent: Dilute [methanol](#) (9 in 10)

Mobile phase: [Acetonitrile](#) and [water](#) (400:600), filtered and degassed

Internal standard solution: 0.7 mg/mL of norethindrone in *Diluent*

Standard stock solution: 0.8 mg/mL of [USP Prednisolone Acetate RS](#) in *Diluent*

Standard solution: 0.04 mg/mL of [USP Prednisolone Acetate RS](#) prepared as follows. Transfer 5.0 mL of *Standard stock solution* to a 100-mL volumetric flask, add 5.0 mL of *Internal standard solution*, dilute with *Diluent* to volume, and mix.

Sample solution: Transfer a quantity of Ophthalmic Ointment nominally equivalent to about 4 mg of prednisolone acetate to a 50-mL centrifuge tube. Add 10.0 mL of [heptane](#), and mix using a vortex mixer for about 2 min to dissolve the Ophthalmic Ointment. Add 5.0 mL of *Internal standard solution* and 20.0 mL of *Diluent*, and mix using a vortex mixer for 2 min. Centrifuge to effect separation of the phases. Withdraw and discard the upper heptane layer. Transfer the lower layer to a 100-mL volumetric flask. Add *Diluent* to volume, and mix.

Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

Mode: LC

Detector: 254-nm diode array

Column: 3.9-mm × 30-cm; packing [L1](#)

Flow rate: 1.5 mL/min

Injection volume: 40 µL

System suitability

Sample: *Standard solution*

[NOTE—The relative retention times for prednisolone acetate and norethindrone are about 1.0 and 1.5, respectively.]

Suitability requirements

Resolution: NLT 4.5 between the prednisolone and norethindrone peaks

Column efficiency: NLT 3000 theoretical plates for the prednisolone peak

Tailing factor: NMT 2.5 for the prednisolone peak

Relative standard deviation: NMT 1.5% for the peak response ratio of prednisolone acetate to norethindrone

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of prednisolone acetate ($C_{23}H_{30}O_6$) in the portion of Ophthalmic Ointment taken:

$$\text{Result} = (R_U/R_S) \times (C_S/C_U) \times 100$$

R_U = peak response ratio of prednisolone acetate to the internal standard peak from the *Sample solution*

R_S = peak response ratio of prednisolone acetate to the internal standard peak from the *Standard solution*

C_S = concentration of [USP Prednisolone Acetate RS](#) in the *Standard solution* (mg/mL)

C_U = nominal concentration of prednisolone acetate in the *Sample solution* (mg/mL)

Acceptance criteria: 90.0%–110.0%

SPECIFIC TESTS

• **STERILITY TESTS (71):** Meets the requirements

• **OTHER REQUIREMENTS:** It meets the requirements for *Particulate and Foreign Matter* and *Container Contents* in [Ophthalmic Products—Quality Tests \(771\)](#), [Drug Product Quality, Universal Tests, Particulate and Foreign Matter](#) and [Container Contents](#).